Naltrexone in the Treatment of Trichotillomania

Learn more about:
Related Clinical Trial
Technology Assisted Treatment for Trichotillomania Leveraging Technological Advancements to Improve the Treatment of Trichotillomania Internet CBT for Trichotillomania and Skin Picking Disorder Developing Effective Response Inhibition Training for Symptom Relief in OCD and Trichotillomania Evaluation and Follow-up of Individuals With Obsessive-Compulsive Disorder and Related Conditions Outcomes of Cognitive Behavioral Therapy (CBT) Interventions Provided by Unlicensed Professionals Evaluation of a Brief Surf the Urge Intervention Feasibility Study for Treating Trichotillomania With Wearable Device and App System Cognitive Behavioral Treatment of Pediatric Trichotillomania Telepsychotherapy for the Treatment of Adolescents With Trichotillomania Stepped Care in the Treatment of Trichotillomania Response Inhibition Training for Individuals With Trichotillomania Cognitive Behavioral Therapy for Trichotillomania Examining Behavior Therapy for Trichotillomania in Children and Adolescents Comprehensive Behavioral (ComB) Model of Treatment for Trichotillomania Methylphenidate in ADHD With Trichotillomania Marinol in Trichotillomania or Obsessive Compulsive Disorder Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors Cognitive Training in Patients With Trichotillomania (Hair-pulling Disorder) Olanzapine in the Treatment of Hair Pulling (Trichotillomania) A Study in Patients With Trichotillomania Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania Inositol in Trichotillomania Trial of Aripiprazole in Trichotillomania Habit Reversal Training for Children and Adolescents With Trichotillomania Naltrexone in the Treatment of Trichotillomania N-Acetylcysteine for Pediatric Trichotillomania Online Response Inhibition Training for Trichotillomania N-Acetyl Cysteine in Trichotillomania Trichotillomania: Group Cognitive-Behavioral Therapy Efficacy of COMB (Comprehensive Behavioral) Model of Treatment of Trichotillomania Milk Thistle in Trichotillomania in Children and Adults Cognitive Behavioral Group Therapy for Trichotillomania (Hair Pulling Disorder) Testing a New Therapy for Trichotillomania Online Treatment of Trichotillomania

Brief Title

Naltrexone in the Treatment of Trichotillomania

Official Title

A Double-blind, Placebo-controlled Study of Naltrexone in Trichotillomania

Brief Summary

      This is an 8-week, double-blind study of Natrexone in the treatment of trichotillomania

Detailed Description

      The goal of the proposed study is to evaluate the efficacy of Naltrexone in trichotillomania.
      Forty subjects with DSM-IV trichotillomania will receive 8 weeks of double-blind Naltrexone
      or placebo. The hypothesis to be tested is that Naltrexone will be effective and well
      tolerated in patients with trichotillomania compared to placebo. The proposed study will
      provide needed data on the treatment of a disabling disorder that currently lacks a clearly
      effective treatment.

Study Phase

Phase 2

Study Type


Primary Outcome

National Institute of Mental Health Trichotillomania Symptom Severity Scale

Secondary Outcome

 Massachusetts General Hospital Hairpulling Scale





Study Arms / Comparison Groups

Description:  Naltrexone


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status


Estimated Enrollment


Start Date

August 2008

Completion Date

December 2012

Primary Completion Date

November 2012

Eligibility Criteria

        Inclusion Criteria:

          1. men and women age 18-75;

          2. current DSM-IV trichotillomania;

          3. hair-pulling primarily due to urges/cravings; and 4) pulling is reported as
             pleasurable the majority of time.

        Exclusion Criteria:

          1. unstable medical illness or clinically significant abnormalities on pre-study
             laboratory tests or physical examination;

          2. history of seizures;

          3. myocardial infarction within 6 months;

          4. current pregnancy or lactation, or inadequate contraception in women of childbearing

          5. clinically significant suicidality;

          6. current or recent (past 3 months) DSM-IV substance abuse or dependence;

          7. illegal substance within 2 weeks of study initiation;

          8. initiation of psychotherapy or behavior therapy from a mental health professional for
             the treatment of trichotillomania within 3 months prior to study baseline;

          9. initiation of a psychotropic medication within 2 months prior to study inclusion;

         10. previous treatment with naltrexone; and

         11. treatment with investigational medication or depot neuroleptics within 3 months, with
             fluoxetine within 6 weeks, or with other psychotropics within 2 weeks prior to study

         12. lifetime history of DSM-IV bipolar disorder type I, dementia, or schizophrenia or any
             other DSM-IV psychotic disorder;

         13. current use of opiates.




18 Years - 75 Years

Accepts Healthy Volunteers



Jon E Grant, M.D., , 

Location Countries

United States

Location Countries

United States

Administrative Informations



Organization ID


Responsible Party

Principal Investigator

Study Sponsor

University of Chicago

Study Sponsor

Jon E Grant, M.D., Principal Investigator, University of Minnesota

Verification Date

January 2014